Endocrine Abstracts

Objective: Metformin is the first-line therapy for PCOS with high metabolic risk, yet a large proportion of patients cannot tolerate it due to associated gastrointestinal adverse events. The alternative pharmacological strategy when metformin cannot be tolerated is not well established in this population. Our aim was to evaluate whether sitagliptin (SITA) preserves metabolic profile in metformin (MET) intolerant PCOS with high metabolic risk.Design and m...

Objective: Impaired glucose homeostasis in PCOS is closely linked to obesity, age and disease phenotype. The potential separate role of reduced GLP-1 response in the development of prediabetes in this population is unclear.Aim: To compare the GLP-1 response after OGTT in a cohort of obese PCOS with normal glucose tolerance (NGT) and prediabetes.Design/participants/methods: Case control study recruited 26 obese Caucasian women with ...

Background: Withdrawal of anti-obesity medication is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. In STEP 1 trial extension participants regained two-thirds of their prior weight loss during the 1-year off-treatment follow-up period after withdrawal of semaglutide 2.4 mg and discontinuation of active lifestyle intervention support. There are some studies implying that metformin might attenuat...

Background: GLP-1 agonism have the potential to affect gastric emptying (GE), yet the reports for subcutaneous semaglutide, currently the most effective GLP-1 RA approved for weight management, remain inconclusive. It has been demonstrated that semaglutide either had no effect on GE or it delayed GE only within the first hour, without late phase retention. Notably, those conclusions were made by an indirect method of estimation of GE through ingestion, absorption and determina...

Background: Obese individuals may perceive the taste of caloric dense food as less intense, resulting in decreased activation of the reward system. Preclinical research provides some insights into the role of GLP-1 in the gustatory coding. The impact of GLP-1 receptor agonists on the tongue and taste perception remains largely unaddressed in clinical settings.Aim: to investigate the impact of semaglutide on the tongue transcriptome, taste perception and ...

ObjectiveFat depot in the tongue that represents 25–30% of the total tongue mass is largely unaddressed. It correlates with body mass index. The response to weight reduction induced by different anti-obesity modalities may vary between body fat compartments. Semaglutide, a long acting GLP-1 receptor agonist (GLP-1 RA), has the potential to reduce body mass with at least 2 to 3 times greater weight reduction than other studied GLP-1 RAs. This is the ...